Mar 5, 2019
Astellas Pharma has teamed up with ReForm Biologics to reduce the viscosity of its clinical-phase biologics. The collaboration will leverage excipients ReForm developed to enable the subcutaneous and device-assisted delivery of large molecules. The project builds on...
Mar 5, 2019
Astellas Pharma (OTCPK:ALPMY +0.9%) will collaborate with Woburn, MA-based ReForm Biologics on reformulating its pipeline of biologic therapies to allow for alternative dosing, specifically subcutaneous injection, more efficient manufacturing and longer product life...
Mar 5, 2019
WOBURN, Mass.–(BUSINESS WIRE)–ReForm Biologics, a privately-held pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a collaboration with Astellas Pharma Inc. (TSE:...
